Changlian Quantong (Wuhan) Technology Co., Ltd – Trademark Portfolio

Entity Type: 99

Changlian Quantong (Wuhan) Technology Co., Ltd holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 12 (Vehicles) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include HVONOGTN. The owner is based in Wuhan, Hubei.

Tianlun Wanjin International Plaza/Tower

Office Room 21-5, 21st Floor, Unit 1

Wuhan, Hubei 430000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

HVONOGTN
HVONOGTN
Registered 2024

Trademark Classifications

Changlian Quantong (Wuhan) Technology Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

12
Vehicles (1 filing)

Vehicles; apparatus for locomotion by land, air or water

Frequently Asked Questions

How many trademarks does Changlian Quantong (Wuhan) Technology Co., Ltd have?

Changlian Quantong (Wuhan) Technology Co., Ltd has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Changlian Quantong (Wuhan) Technology Co., Ltd file in?

Changlian Quantong (Wuhan) Technology Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 12 (Vehicles). Class 12 covers vehicles; apparatus for locomotion by land, air or water.

What are Changlian Quantong (Wuhan) Technology Co., Ltd's most well-known trademarks?

Changlian Quantong (Wuhan) Technology Co., Ltd's registered trademark portfolio includes well-known marks such as HVONOGTN. These are among 1 currently registered trademark in the portfolio.

What is Changlian Quantong (Wuhan) Technology Co., Ltd's trademark registration success rate?

Changlian Quantong (Wuhan) Technology Co., Ltd has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.